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Abstract. – OBJECTIVE: Upper gastrointesti-
nal bleeding (UGIB) is a cause of Emergency De-
partment (ED) visits. Peptic ulcer secondary to H. 
pylori (HP) infection and/or to the use of NSAIDs 
is the most frequent cause. The aim of the study 
is to evaluate directly in the ED the prevalence of 
HP infection through Urea Breath test (UBT) in 
patients admitted to the ED for UGIB.
PATIENTS AND METHODS: We enrolled 87 pa-
tients (58M/29F) with a mean age of 63.8 + 11.7 
yrs with an active UGIB who performed EGDS 
and UBT.
RESULTS: 34.4% of patients performing EGDS 
and UBT resulted positive to HP. Peptic ulcer was 
present in 20/30 (66.7%) of HP+ compared to 20/57 
(35.1%) of HP- (p<0.001), and also gastritis and/or 
duodenitis were mostly present in HP+ (23.3% vs. 
15.8%) (p<0.05). A biopsy was performed in only 
31% of patients with a positive rate of 33.3%. In 78% 
we obtained a correspondence between UBT and 
biopsy results. Compared to biopsy result, we ob-
tained for UBT a positive predictive value (PPV) of 
71% and a negative predictive value (NPV) of 80%. 
Taking the UBT as a gold standard, we obtained for 
biopsies a PPV of 69% and a NPV of 85%.
CONCLUSIONS: Our study confirms that the 
use of UBT directly in ED in patients with UGIB al-
lows for a rapid, reliable and non-invasive diagno-
sis of HP infection as a causative agent for bleed-
ing, thus permitting a right etiological treatment.
Key Words:
Upper gastrointestinal bleeding, Helicobacter pylo-
ri, Urea breath test, Emergency Department. 
Introduction
Melena and hematemesis, as an expression of an 
UGIB, represent among the most common causes 
of admissions to the Emergency Department (ED). 
According to recent estimates, the in-hospital 
management costs are considerably high, reaching 
about 3’400$ for uncomplicated nonvariceal bleed-
ing, and around 5’600 $ for complicated ones1.
In all cases, peptic ulcer represents the most 
frequent and important cause of acute UGIB, 
being responsible for approximately 35 to 60% of 
episodes. The main risk factors for peptic ulcer 
development are well known: HP infection and 
the use of NSAIDs2.
Detection of HP during bleeding can be a chal-
lenge, as the accuracy of the diagnostic methods is 
diminished in this setting. The invasive methods 
(histology, culture and rapid urease test) need bi-
opsies, and this could be a problem. Some study 
showed that urease test has a reduced sensitivity 
(25% to 40%), with many false negatives in case of 
UGIB3-5. This suggests that blood plasma has a buff-
ering effect and adversely affects the urease activity. 
Fantry et al6 stated that the position of nasogastric 
tubes and gastric lavage before the endoscopy may 
reduce the bacterial load, thus leading to false-neg-
ative diagnostic test. Colin et al7 found a low perfor-
mance, with sensitivity around 30%, for the other 
invasive tests (i.e., histology and culture), too.
Finally, serology is associated with a high 
false-positive rate because antibodies persist even 
after the infection has been eradicated8.
As regards noninvasive methods, both urea 
breath test (UBT) and the stool antigen test (HP-
SA) have an excellent accuracy9, even if UBT re-
quires that the patient be off proton pump inhibi-
tors and antibiotics prior to testing, and the stool 
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test is not preferred in clinical practice because it 
involves the collection of feces10.
However, considering that both serologic, his-
tologic tests and HPSA require particularly long 
technical waiting times, the most indicated test 
to be conducted in emergency for acute UGIB is 
undoubtedly UBT11-13. Furthermore, in a system-
atic review by Calvet et al14 evaluating 11 studies 
with a total of 811 patients, the authors reported for 
UBT a sensitivity of 93%, specificity of 88% and 
a positive predictive value of 97%. However, given 
that false negatives do exist, when there is clinical 
suspicion of the presence of HP, but the first UBT 
is negative, this result must be taken with caution 
and a second UBT should be conducted15.
Nowadays, for a bleeding peptic ulcer, the 
available strategies are based on a continuous 
treatment with proton pump inhibitors (PPI) and 
HP eradication in patients who might have an 
increased bleeding risk. Therefore, the Europe-
an Society of Gastroenterology (ESGE) recom-
mends, for patients bleeding from a peptic ulcer, 
a search for HP directly at acute presentation, so 
as to promptly start a possible eradication therapy 
and to reduce the risk of recurrence16. Moreover, 
the International Consensus Recommendations 
on the management of nonvariceal gastrointesti-
nal bleeding15 stress the importance of HP test-
ing, eradication and successful treatment confir-
mation. Indeed, a metanalysis by Gisbert et al17 
underlines how convenient eradication therapy 
is with respect to performing an EGDS once the 
bleeding recurrence has occurred.
Patients coming to ED with melena or he-
matemesis are initially evaluated, stabilized and, 
in the majority of cases, an esophagogastro-
duodenoscopy (EGDS) is required in order to 
establish the etiological diagnosis, treatment and 
hemostasis. However, in the clinical practice of 
UGIB, it is uncommon to perform a biopsy for 
HP identification during endoscopy, due to the 
presence of blood onto the gastric walls or when 
the exam is performed in the emergency during 
night or holidays18,19.
This represents an issue for the future therapy 
prescription at discharge: indeed, these patients 
start a high-dose PPI treatment, which delays a 
possible Urea Breath Test (UBT) for the search 
of HP, with an important impact on management 
costs and recurrence risk.
Recent literature clearly shows that in a group 
of patients with UGIB, where HP was not inves-
tigated or the eradication therapy failed, re-bleed-
ing risk at one year was present in 1/3 of the 
study population16. On the other side, a Japanese 
study demonstrated that patients with a success-
ful eradication did not show further episodes of 
bleeding20.
With this background, the aim of our study 
is to estimate the prevalence of HP infection in 
patients admitted to the ED for UGIB via UBT, 
to quickly establish a rapid, reliable and non-inva-
sive diagnosis of the bleeding cause.
Patients and Methods
This is a monocentric, prospective study con-
ducted at the ED of Fondazione Policlinico Uni-
versitario A. Gemelli IRCCS. All of the enrolled 
patients, who came with acute UGIB, under-
went routine blood tests (full blood cell count, 
blood chemistry test, coagulation tests), UBT and 
EGDS when appropriate.
Study Population
We enrolled 87 (58M/29F) consecutive pa-
tients, from the 1st of June 2019 to the 1st of June 
2020, admitted to our ED with UGIB (melena 
and/or hematemesis).
Inclusion criteria
• Melena and/or hematemesis (current/within 
the previous 48 hours).
• Fasting for at least 6 hours before the test.
• Signature of informed consent.
Exclusion criteria
• < 18 years old.
• Suspected or confirmed pregnancy.
• Hemodynamically unstable patients.
• Antibiotics, bismuth compounds and proton 
pump inhibitors (PPIs) for at least two weeks.
• Patients with a previous gastric resection.
• Unable to swallow or with a nasogastric tube.
• Patients could withdraw from the study upon 
written request.
The flowchart representing the enrollment pro-
cess, with the application of exclusion criteria, is 
shown in Figure 1.
Urea Breath Test
The commercial brand of the 13C-UBT that we 
used was UBT-Kit (Richen Europe, Milan, Italy). 
We collected an exhaled air sampling at baseline 
(before urea administration): the patient is asked to 
take a deep breath and blow in a sachet exhaling all 
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the air contained in the lungs. At this point, the pa-
tient drinks a solution of 13C labeled urea (75 mgr.) 
mixed with citric acid (to reduce gastric emptying) 
in 200 ml of water and waits for thirty minutes 
without eating or drinking. At the end, the entire 
procedure is repeated in a second sachet.
Breath tests were collected in twice, with a 
concordance of 98,5% (Cohen’s test).
The exhaled air is then analyzed, within 24 
hours, by an infrared spectrometer “IR-force 200” 
by Beijing Richen-force Science and Technology 
Co. Ltd., which allows to measure the amount of 
CO2 13C with respect to the total of expired CO2 
12C in three minutes.
IR Force – 200 is an instrument designed to 
guarantee an efficient and rapid response in the 
diagnosis of HP infections with an optimal per-
formance for small and medium routines.
The instrument is user-friendly and does not 
require specialized personnel for its use.
The difference in the ratios between the base-
line value and the post-urea value is referred to 
as delta over baseline (DOB). A DOB >3.50 ppm 
after thirty minutes is commonly considered di-
agnostic for HP infection.
EGDS
All EGDSs were performed within 48 hours 
from the access to ED by expert endoscopist 
with a high-resolution double-channel video en-
doscope (Olympus GIF 2-T scope, Tokyo, Japan).
Ethics Statement
The study was conducted in accordance with 
the Declaration of Helsinki. None of the patients 
or authors received any honorary or economic 
benefits for the participation in this work.
The study was approved on 29th March 2019 
by the Ethical Committee of the Università Cat-
tolica del Sacro Cuore of Rome, with ID 2302, 
Protocol No. 14245/19.
Statistical Analysis
A descriptive statistical analysis was per-
formed using absolute and relative frequencies, 
mean and standard deviation (SD), when appro-
priate, for demographic and clinical character-
istics of surveyed patients and clinical outcome 
parameter. Statistically significant differences in 
clinical outcome parameter, between hospitalized 
and non-hospitalized patient, were tested through 
t-test, Wilcoxon rank-sum (Mann-Whitney test), 
Chi-square test, as applicable. Association be-
tween length of stay and other continuous vari-
ables was tested using Spearman correlation. 
Multi-variate analysis was performed to evaluate 
the impact of independent variables in predicting 
length of stay. The statistical significance level 
was set at p< 0.05 and all the analyses were car-
ried out by using the software “Stata MP 14 for 
Mac” (Stata Corp., Lakeway, TX, USA).
Results
We enrolled 87 patients (58M/29F) with a 
mean age of 63.8 + 11.7 yrs. None of the patients 
had any problem in completing the UBT. UBT 
(DOB>3.5) was positive in 30 out of 87 patients 
(34.4%) with a mean DOB value of 22.37 + 15.11 
ppm. The mean age of positive patients was 64 
+10.4 yrs, meanwhile for negative patients was 
63.7 + 11.9 yrs (p=ns). Prevalence of HP+ was 
significantly higher in males compared to females 
(80% vs. 20%; p<0.001) (Figure 1).
Meanwhile, in negative patients (HP-) we ob-
served only a slightly higher prevalence of males 
34M/23F (59.7% vs. 40.3% p=ns). Interesting-
ly, females showed a significant higher mean 
DOB value compared to males (51.70±35.11 vs. 
15.7±11.6; respectively p<0.001).
Demographic characteristics are shown in Table I.
Clinical Features
Clinical features and statistical significance are 
summarized in Table I.
As regards clinical presentation such as he-
matemesis, melena or syncope we did not ob-
serve any difference between the two groups and 
previous GI bleeding occurred with the same 
frequency.
Figure 1. Enrollment process flowchart.
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A history of coronary artery disease was re-
ferred in 13.3% of HP+ compared to 8.8% of HP- 
(p<0.05), meanwhile no difference was observed 
for cerebrovascular disease. As regards medi-
cation history, interestingly we observed that 
NSAID had been used only in 3/30 (10.0%) of 
HP+ compared to 14/57 (24.6%) in HP- (p<0.001), 
also antiplatelet agents were used more frequent-
ly in HP- compared to HP+ (21.0% vs. 16.7%) 
(p<0.05) suggesting a prevalent role of this drugs 
in the genesis of GI bleeding. Low hemoglobin 
levels (<9 g/dL) on admission were significantly 
less prevalent in HP+ compared to HP- (56.7% vs. 
43.9%, respectively) (p<0.05) (Table I).
Endoscopic Findings
Endoscopic findings in HP+ and HP- are sum-
marized in Table II.
As expected, peptic ulcer was present in 20/30 
(66.7%) of HP+ compared to 20/57 (35.1%) of 
HP- (p<0.001), and also gastritis and/or duodeni-
tis were mostly present in HP+ (23.3% vs. 15.8%) 
(p<0.05). Another interesting result is that in 36% 
of HP- patients a definite source of bleeding was 
not detected through upper GI endoscopy, com-
pared to only 3.3% in HP+ (p<0.001), suggesting 
a bleeding from the small or large bowel.
Biopsies
A biopsy during endoscopy was performed in 
only 27 out of 87 (31%) patients with a positive 
rate of 33.3% (9/27). In 78% (21 out of 27 cases) 
we obtained a correspondence between UBT and 
biopsy results, on the contrary in 6/27 (22.2%) 
the results were discordant. In particular, in 4 
patients the biopsy resulted positive and the UBT 
negative, while in the other 2 patients UBT result-
ed positive and the biopsy negative. Compared 
to biopsy result, we obtained for UBT a positive 
predictive value (PPV) of 71% and a negative pre-
Table I. General characteristics of overall population, HP positive (HP+) and negative (HP-) patients.
 Overall HP+ HP- p-value
Demographics
Mean Age 63.8 + 11.7 64+ 10.4 63.7 + 11.9 ns
Gender M 58 (66.7%) M 24 (80.0%) M 34 (59.7%) < 0.001 
 F 29 (33.3%) F 6 (20.0%) F 23 (40.3%) 
Mean DOB by gender (for HP+)  M 15.03 ± 11,6  < 0.001
  F 51.70 ± 35,11  
Clinical presentation
Hematemesis 22 (25.3%) 6 (20.0%) 16 (28.1%) ns
Melena 67 (77.0%) 22 (73.3%) 45 (79.0%) ns
Syncope 11 (12.6%) 5 (16.7%) 6 (10.5%) ns
Hb < 9 g/dL (admission) 42 (48.3%) 17 (56.7%) 25 (43.9%) < 0.05
Length of stay (LOS) < 3 days  65 (74.7%) 25 (83.3%) 40 (70.2%) < 0.001
Medical historyand medications
Previous bleeding 18 (20.7%) 8 (26.7%) 10 (17.5%) ns
Coronary Artery
Disease 9 (10.3%) 4 (13.3%) 5 (8.8%) < 0.05
Cerebrovascular disease 3 (3.5%) 1 (3.3%) 2 (3.5%) ns
NSAID 17 (19.5%) 3 (10.0%) 14 (24.6%) < 0.001
Antiplatelet 17 (19.5%) 5 (16.7%) 12 (21.1%) < 0.05
Warfarin 3 (3.45%) 1 (3.3%) 2 (3.5%) ns
DOAC 7 (8.1%) 4 (13.3%) 3 (5.3%) < 0.05
Table II. EGDS findings in HP+ and HP- patients.
 Endoscopic diagnosis HP+ (n = 30) HP- (n = 57) p-value
Peptic ulcer 20 (66.7%) 20 (35.1%) < 0.001
Gastritis/Duodenitis 7 (23.3%) 9 (15.8%) < 0.05
Variceal bleeding 0 (0.0%) 1 (1.7%) ns
Esophagitis 1 (3.3%) 3 (5.3%) ns
Gastric polyposis 0 (0.0%) 3 (5.3%) ns
Delafoy ulcer 1 (3.3%) 0 (0.0%) ns
Negative EGDS 1 (3.3%) 21 (36.8%) < 0.001
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dictive value (NPV) of 80%. Taking the UBT as a 
gold standard, we obtained for biopsies a PPV of 
69% and a NPV of 85%.
Length Of Stay (LOS)
83% of HP+ patients had a hospitalization of 
<3 days, compared to 70% of HP-, reaching a 
statistically significant difference (p<0.001), thus 
suggesting that the research for HP infection in 
ED and its positivity reached an etiological diag-
nosis of UGIB.
Discussion
Our study showed that the most common clin-
ical manifestation of UGIB is melena, that males 
are more infected by HP than female, meanwhile, 
the DOB value observed in females is significant-
ly higher than males. This data is confirmed by 
Martel et al21 that found an association between 
HP infection and male gender with an OR of 1.16; 
this close association could explain also the high-
er prevalence of peptic ulcer and gastric cancer 
in males21.
The DOB value seems to be linked to the HP 
density22. Indeed, some authors found a strong 
correlation among UBT value, HP load and gas-
tric inflammation23.
Some authors speculated that gastric emptying 
rates, bacterial colonization density, or even HP 
urease production in the host depends on gender 
difference24.
The higher level of DOB value observed in fe-
males and the consequent HP density could have 
an implication in the well-known less successful 
eradication rate.
HP prevalence is variable between 19% and 
88% and depends on various factors such as 
geographical location, patient’s age, sanitation, 
and socioeconomic status25-27. We found that one-
third of our population with UGIB harbour HP in 
their stomach.
In the early 2000s, some researches were pub-
lished12,13,28,29 on the importance of researching 
HP infection in patients with acute bleeding 
through the UBT. Most of them indicate the use-
fulness of this noninvasive test to diagnose HP 
infection in patients with bleeding peptic ulcers, 
suggesting that the test was not affected by the 
presence of blood in the stomach.
In particular, these studies12,13,28,29 evaluated HP 
infection through UBT in the setting of acute 
UGIB with reasonably accurate results. In the 
study by Valayos et al13, the authors found a posi-
tive predictive value of 96%, but a negative predic-
tive value of 54% suggesting that false negatives 
might often occur. Winiarski et al13, instead, ob-
tained a much superior negative predictive value.
They all concluded that larger studies are howev-
er required prior to advocating a negative UBT test 
as a sufficiently accurate result in this setting.
To our knowledge, so far, no investigations 
have been published on this topic. Therefore, we 
wanted to carry out a study to give an update 
nowadays on the efficacy of UBT directly in ED 
in patients with UGIB and on the prevalence of 
HP infection in these patients. Compared to bi-
opsy result, in our study, we obtained, for UBT, 
a positive predictive value (PPV) of 71%, and a 
negative predictive value (NPV) of 80%. Some 
other interesting features emerge from our study: 
we found an association between recurrence of 
bleeding and those who had not previously been 
tested and treated for eradication of HP, hence the 
need to test it in the ED so as to avoid missing 
diagnosis. Hypothetically HP infection should 
be tested once the acute bleed is over. However, 
this introduces the problem of having to hold acid 
suppression for 2 weeks prior to testing, definitely 
not recommended in a patient who recently bled. 
Regardless of which test one uses, it is important 
to test for and treat HP infection in a patient with 
bleeding peptic ulcer.
Our study shows that a higher proportion of 
patients in the HP+ group had a coronary ar-
tery disease, suggesting a role of HP antigens 
in the atherosclerotic plaque instability via a 
cross-mimicry mechanism30.
As expected, 24% of HP- patients used NSAIDs 
and this was the cause of bleeding, likewise for 
those HP- patients under antiplatelet.
Our data confirm that treatment with DOAC, 
rather than warfarin, in patients harboring HP in 
their stomach favors GI bleeding16,31-33.
Concerning endoscopy, our findings support 
a milestone in literature that is the association of 
HP with peptic ulcer34-36, more common in men 
with a mean age around 60 years37.
A further proof that HP is one of the most rele-
vant risk factors for upper GI bleeding is the fact 
that 40% of HP- patients were negative at EGDS, 
therefore suggesting a lower GI bleeding.
We want to stress the concept that biopsies for 
HP are rarely performed in acute UGIB18: in our 
case, only 27 out of 87 pts performed biopsies 
and only 9 of these resulted positive. With this in 
mind, the most important finding in our study is 
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that if we had not tested all these patients in ED, 
we would have missed 21 diagnoses of HP. Thus, 
we increased the HP diagnoses by 233% com-
pared to biopsy. Missing diagnoses would have 
translated into future recurrences of bleeding38,39, 
further admissions in the ED and consequent in-
crease in healthcare costs.
The determination HP through UBT directly 
in ED has also an implication in the LOS of these 
patients, indeed 83% of HP+ patients had a LOS in 
the BOU of ED of less than 3 days. Having diag-
nosed HP in the ED as a cause of bleeding allowed 
a faster management of these patients and they 
were discharged with the proper diagnosis and 
treatment directly from ED. On the other hand, 
30% of HP- patients had to be hospitalized in a 
ward in order to reach the correct diagnosis, and, 
once again, this percentage would have been quite 
higher if we had not tested these patients in ED.
Limitations
The presence of blood onto the gastric walls 
might have altered stomach’s pH, causing some 
false negatives at UBT.
Furthermore, the upright position that should 
be maintained during the UBT was not always 
possible in the emergency setting (e.g., clinically 
unstable patients; considerable blood loss with se-
vere anemia). So, we could have underestimated 
HP infection in these patients.
Finally, considering that many of these patients 
referred to ED of our hospital for the acute bleed-
ing event but not for follow up in the outpatient 
clinic, data confirming a successful eradication 
of HP after proper discharge therapy are missing.
It would have been interesting comparing other 
methods such as the detection of monoclonal anti-
bodies in the feces or the culture on biopsies with 
consequent antibiogram. However, these methods 
require a microbiology laboratory open 24 hours, 
7 days and a long time waiting to acquire the re-
sults of HP antibiotic sensibility.
Conclusions
In the clinical practice with UBT we increased 
the diagnosis of HP by 233% compared to biopsy 
results. The methodology utilized was simple, as 
the test per se is easy to conduct.
The use of this method would be recommend-
ed in all EDs, in order to allow the etiologic diag-
nosis and appropriate treatment, while reducing 
the LOS.
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